Skip to main content
Premium Trial:

Request an Annual Quote

Startup Blackfield Supporting AstraZeneca with Genomics, Computational Biology Services

NEW YORK (GenomeWeb News) – German startup biotech firm Blackfield today announced a collaboration with AstraZeneca in support of one of the biopharmaceutical firm's oncology drug development programs.

Blackfield will apply its genomics technologies and computational biology capabilities to validate preclinical models in support of AstraZeneca's program it said. Further details of AstraZeneca's program were not revealed.

Blackfield said that today's deal is its fourth since starting up a year ago. It also has service agreements with Janssen Pharmaceuticals, a division of Johnson & Johnson; Merck KGaA; and Boehringer Ingelheim.

Financial and other terms of the deal with AstraZeneca were not disclosed.

Based in Cologne, Blackfield generates datasets of genomic changes in various types of cancer, then applies computation biology to support the development of methods to molecularly diagnose and treat cancer.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.